Holen Sie sich die Stockscreener-App
199.63
0.56%
-1.2534
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$200.88
Offen:
$202.84
24-Stunden-Volumen:
435.79K
Relative Volume:
0.45
Marktkapitalisierung:
$21.91B
Einnahmen:
$10.52B
Nettoeinkommen (Verlust:
$999.00M
KGV:
23.87
EPS:
8.3628
Netto-Cashflow:
$1.22B
1W Leistung:
+0.27%
1M Leistung:
-3.44%
6M Leistung:
+9.21%
1J Leistung:
+18.33%
1-Tages-Spanne:
$199.39
$205.00
1-Wochen-Bereich:
$195.39
$205.00
52-Wochen-Spanne:
$157.20
$213.50
Quest Diagnostics Inc Stock (DGX) Company Profile
Firmenname
Quest Diagnostics Inc
Sektor
Branche
Telefon
(973) 520-2700
Adresse
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
199.39 | 22.07B | 10.52B | 999.00M | 1.22B | 8.3628 |
|
TMO
Thermo Fisher Scientific Inc
|
466.31 | 176.79B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
186.84 | 131.71B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
572.75 | 45.48B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
111.45 | 31.55B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
285.83 | 27.79B | 3.17B | 642.63M | 516.49M | 10.77 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-08-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-04-02 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-01-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | Jefferies | Buy |
| 2024-10-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | Fortgesetzt | Evercore ISI | In-line |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-02-07 | Hochstufung | Jefferies | Hold → Buy |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2023-12-12 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-06-29 | Eingeleitet | Piper Sandler | Neutral |
| 2023-05-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-23 | Eingeleitet | Evercore ISI | In-line |
| 2022-11-17 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-08-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-04-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-02-23 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-02 | Herabstufung | Jefferies | Buy → Hold |
| 2022-01-28 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-05-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-03-12 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | Hochstufung | Argus | Hold → Buy |
| 2020-07-29 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-09 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-04-28 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-04-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | Eingeleitet | Wells Fargo | Underweight |
| 2020-01-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-12-19 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | Herabstufung | Goldman | Neutral → Sell |
| 2019-04-02 | Hochstufung | Jefferies | Hold → Buy |
| 2019-03-18 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-01-31 | Herabstufung | Argus | Buy → Hold |
| 2019-01-17 | Eingeleitet | UBS | Neutral |
| 2019-01-03 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | Herabstufung | Goldman | Buy → Neutral |
Alle ansehen
Quest Diagnostics Inc Aktie (DGX) Neueste Nachrichten
Quest Diagnostics Elects Former Walgreens Boots Alliance CEO Timothy Wentworth to Board of Directors - Minichart
Quest Diagnostics (DGX) Appoints Timothy Wentworth to Board of D - GuruFocus
Quest Diagnostics adds ex-Walgreens CEO to board - Investing.com
Quest Diagnostics Elects Timothy Wentworth, Former CEO of Walgreens Boots Alliance, Evernorth Health Services and Express Scripts, to Board of Directors - Quest Diagnostics Newsroom
Ex-Walgreens CEO who ran $100B Express Scripts joins Quest board - Stock Titan
Quest Diagnostics (DGX) Down 4.2% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Quest Diagnostics Incorporated $DGX Position Trimmed by Schroder Investment Management Group - MarketBeat
Quest Diagnostics Expands Preventive Reach With Shield Colorectal Blood Test - simplywall.st
First Trust Advisors LP Raises Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Banque Cantonale Vaudoise Acquires 5,985 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Should You Keep DGX Shares in Your Investment Portfolio? - Bitget
Should You Continue to Hold DGX Stock in Your Portfolio? - The Globe and Mail
Barclays PLC Has $47.86 Million Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Insider Selling: Quest Diagnostics (NYSE:DGX) EVP Sells $1,146,115.18 in Stock - MarketBeat
Insider Selling: Quest Diagnostics (NYSE:DGX) SVP Sells 3,878 Shares of Stock - MarketBeat
Plewman Patrick, Quest Diagnostics SVP, sells $588k in stock - Investing.com Nigeria
Plewman Patrick, Quest Diagnostics SVP, sells $588k in stock By Investing.com - Investing.com Canada
Dimensional Fund Advisors LP Has $363.51 Million Stake in Quest Diagnostics Incorporated $DGX - MarketBeat
Implied Volatility Surging for Quest Diagnostics Stock Options - Nasdaq
Genomics Services Market Projected to Surpass USD 25.18 Billion by 2035; Increasing Genetic Disorders’ Prevalence is Driving Market Growth Globally – SNS Insider - GlobeNewswire Inc.
Elo Mutual Pension Insurance Co Makes New $2.03 Million Investment in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics (NYSE: DGX) EVP sells shares and disposes stock for taxes - Stock Titan
Quest Diagnostics (NYSE: DGX) SVP sells 526 shares in plan - Stock Titan
Quest Diagnostics (NYSE: DGX) CEO discloses 10,000-share stock sale - Stock Titan
Quest Diagnostics (DGX) SVP sells and withholds shares under plan - Stock Titan
Quest Diagnostics (NYSE: DGX) SVP covers tax obligations with share sale - Stock Titan
Quest Diagnostics (NYSE: DGX) SVP reports tax-withholding stock disposition on Form 4 - Stock Titan
Quest Diagnostics Hits New 52-Week High of $213.50, Up 49.79% - Markets Mojo
Quest Diagnostics Incorporated (NYSE:DGX) Short Interest Update - MarketBeat
Quest Diagnostics Remains a Dominant Competitor in Independent Labs - Morningstar
Catherine Doherty reports 27,598 DGX share dispositions in Form 144 (NYSE: DGX) - Stock Titan
DGX insider sale notice (DGX) — 526 vested shares; prior 1,111 sold - Stock Titan
Insider sale notice for DGX (DGX): Plewman lists proposed share disposals - Stock Titan
Victory Capital Management Inc. Sells 465,252 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
DGX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Quest Diagnostics launches AI tool to analyze lab results By Investing.com - Investing.com Canada
DGX (NYSE: DGX) Form 144 shows proposed sale of 10,000 shares - Stock Titan
Quest Diagnostics Rolls Out Gemini-Powered AI Tool to Explain Lab Results - marketscreener.com
Quest Diagnostics introduces AI companion to help patients understand and act on lab test results - marketscreener.com
Quest Diagnostics Introduces Ai Companion to Help Patients Understanding and Act on Lab Test Results - marketscreener.com
Quest Diagnostics Inc. (NYSE:DGX) Stands Out as a Sustainable Dividend Stock - ChartMill
Quest Diagnostics Incorporated $DGX Position Lowered by IVY Lane Capital Management LLC - MarketBeat
Bahl & Gaynor Inc. Decreases Stock Position in Quest Diagnostics Incorporated $DGX - MarketBeat
APG Asset Management N.V. Cuts Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Incorporated $DGX Shares Bought by American Century Companies Inc. - MarketBeat
DGX SEC FilingsQuest Diagnostics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Quest Diagnostics Incorporated $DGX Shares Sold by Vestmark Advisory Solutions Inc. - MarketBeat
Quest Diagnostics Incorporated $DGX Shares Acquired by Mitsubishi UFJ Asset Management Co. Ltd. - MarketBeat
A Look At Quest Diagnostics (DGX) Valuation After Recent Share Price Momentum - Yahoo Finance
Quest Diagnostics (NYSE:DGX) Sets New 1-Year HighWhat's Next? - MarketBeat
Finanzdaten der Quest Diagnostics Inc-Aktie (DGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.76%
0.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):